Top

Published in:

09-05-2022 | Wound Debridement | Original Article

Nonexposed antiresorptive agent-related osteomyelitis of the jaw: a single-center cohort study

Authors: Takuma Watanabe, Takeshi Yoshida, Sachi Akizuki, Shigeki Yamanaka, Kazumasa Nakao, Shizuko Fukuhara, Keita Asai, Ryuji Uozumi, Kazuhisa Bessho

Published in: Journal of Bone and Mineral Metabolism | Issue 4/2022

Abstract

Introduction

The nonexposed variant of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) presents with nonspecific clinical findings. The diagnosis of nonexposed ARONJ poses a critical challenge, and there is little evidence regarding its treatment and outcomes. This study aimed to examine the clinical outcomes in patients with nonexposed antiresorptive agent-related osteomyelitis of the jaw (AROMJ). The terms ARONJ and AROMJ were used separately in this study.

Materials and methods

We enrolled patients with nonexposed AROMJ (osteomyelitis of the jaw without bone exposure associated with antiresorptive agents) with partial reference to an existing position paper on ARONJ. The initiating event of osteomyelitis was limited to periodontitis. Based on the findings of bone scintigraphy, panoramic radiography, computed tomography, and histopathological examination, we also used the hierarchical diagnostic criteria (HDC) for osteomyelitis of the jaw.

Results

There were 58 confirmed cases of nonexposed AROMJ based on the HDC. All patients had sufficient clinical findings to be diagnosed with nonexposed AROMJ as osteomyelitis underwent extraction with bone debridement. The healing rate was 93.1% (54/58). Univariable analysis showed a strong association between the healing status and malignant disease, while multivariable analysis showed no strong association between them.

Conclusions

The present study had a relatively large sample size of patients with nonexposed AROMJ. The primary disease in patients with nonexposed AROMJ may not have a strong association with the healed status of the lesion. Based on its high healing rate, extraction with bone debridement in confirmed nonexposed AROMJ may prevent progression.

Available only for authorised users

Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK et al. (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3–23. https://doi.org/10.1002/jbmr.2405CrossRefPubMed

Allen MR (2015) Medication-related osteonecrosis of the jaw: basic and translational science updates. Oral Maxillofac Surg Clin North Am 27:497–508. https://doi.org/10.1016/j.coms.2015.06.002CrossRefPubMed

Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117. https://doi.org/10.1016/S0278-2391(03)00720-1CrossRefPubMed

Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons (2007) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65:369–376. https://doi.org/10.1016/j.joms.2006.11.003

Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, American Association of Oral and Maxillofacial Surgeons (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 67 Supplement:2–12. https://doi.org/10.1016/j.joms.2009.01.009

Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F, American Association of Oral and Maxillofacial Surgeons (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J Oral Maxillofac Surg 72:1938–1956. https://doi.org/10.1016/j.joms.2014.04.031

Japanese Allied Committee on Osteonecrosis of the Jaw, Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Nagata T, Urade M, Shibahara T, Toyosawa S (2017) Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab 35:6–19. https://doi.org/10.1007/s00774-016-0810-7CrossRef

Mawardi H, Woo SB (2015) Medication-related osteonecrosis of the jaws, stage 0-do we need stage 0 any more? J Oral Maxillofac Surg 73:797. https://doi.org/10.1016/j.joms.2014.12.028CrossRefPubMed

Junquera L, Gallego L (2008) Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant? J Oral Maxillofac Surg 66:1516–1517. https://doi.org/10.1016/j.joms.2008.02.012CrossRefPubMed

10.

Shimamoto H, Grogan TR, Tsujimoto T, Kakimoto N, Murakami S, Elashoff D, Aghaloo TL, Tetradis S (2018) Does CBCT alter the diagnostic thinking efficacy, management and prognosis of patients with suspected Stage 0 medication-related osteonecrosis of the jaws? Dento Maxillo Fac Radiol 47:20170290. https://doi.org/10.1259/dmfr.20170290CrossRef

11.

Soundia A, Hadaya D, Mallya SM, Aghaloo TL, Tetradis S (2018) Radiographic predictors of bone exposure in patients with stage 0 medication-related osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol 126:537–544. https://doi.org/10.1016/j.oooo.2018.08.005CrossRefPubMedPubMedCentral

12.

Vescovi P, Campisi G, Fusco V, Mergoni G, Manfredi M, Merigo E, Solazzo L, Gabriele M, Gaeta GM, Favia G, Peluso F, Colella G (2011) Surgery-triggered and non surgery-triggered bisphosphonate-related osteonecrosis of the jaws (BRONJ): a retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol 47:191–194. https://doi.org/10.1016/j.oraloncology.2010.11.007CrossRefPubMed

13.

Graziani F, Vescovi P, Campisi G, Favia G, Gabriele M, Gaeta GM, Gennai S, Goia F, Miccoli M, Peluso F, Scoletta M, Solazzo L, Colella G (2012) Resective surgical approach shows a high performance in the management of advanced cases of bisphosphonate-related osteonecrosis of the jaws: a retrospective survey of 347cases. J Oral Maxillofac Surg 70:2501–2507. https://doi.org/10.1016/j.joms.2012.05.019CrossRefPubMed

14.

Ruggiero SL, Kohn N (2015) Disease stage and mode of therapy are important determinants of treatment outcomes for medication-related osteonecrosis of the jaw. J Oral Maxillofac Surg 73:S94–S100. https://doi.org/10.1016/j.joms.2015.09.024CrossRefPubMed

15.

Kim HY, Lee SJ, Kim SM, Myoung H, Hwang SJ, Choi JY, Lee JH, Choung PH, Kim MJ, Seo BM (2017) Extensive surgical procedures result in better treatment outcomes for bisphosphonate-related osteonecrosis of the jaw in patients with osteoporosis. J Oral Maxillofac Surg 75:1404–1413. https://doi.org/10.1016/j.joms.2016.12.014CrossRefPubMed

16.

Hayashida S, Soutome S, Yanamoto S, Fujita S, Hasegawa T, Komori T, Kojima Y, Miyamoto H, Shibuya Y, Ueda N, Kirita T, Nakahara H, Shinohara M, Umeda M (2017) Evaluation of the treatment strategies for medication-related osteonecrosis of the jaws (MRONJ) and the factors affecting treatment outcome: a multicenter retrospective study with propensity score matching analysis. J Bone Miner Res 32:2022–2029. https://doi.org/10.1002/jbmr.3191CrossRefPubMed

17.

El-Rabbany M, Lam DK, Shah PS, Azarpazhooh A (2019) Surgical management of medication-related osteonecrosis of the jaw is associated with improved disease resolution: a retrospective cohort study. J Oral Maxillofac Surg 77:1816–1822. https://doi.org/10.1016/j.joms.2019.03.040CrossRefPubMed

18.

Vanpoecke J, Verstraete L, Smeets M, Ferri J, Nicot R, Politis C (2020) Medication-related osteonecrosis of the jaw (MRONJ) stage III: conservative and conservative surgical approaches versus an aggressive surgical intervention: a systematic review. J Craniomaxillofac Surg 48:435–443. https://doi.org/10.1016/j.jcms.2020.02.017CrossRefPubMed

19.

Hutchinson M, O’Ryan F, Chavez V, Lathon PV, Sanchez G, Hatcher DC, Indresano AT, Lo JC (2010) Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure. J Oral Maxillofac Surg 68:2232–2240. https://doi.org/10.1016/j.joms.2010.05.003CrossRefPubMed

20.

Fedele S, Porter SR, D’Aiuto F, Aljohani S, Vescovi P, Manfredi M, Arduino PG, Broccoletti R, Musciotto A, Di Fede O, Lazarovici TS, Campisi G, Yarom N (2010) Nonexposed variant of bisphosphonate –associated osteonecrosis of the jaw: a case series. Am J Med 123:1060–1064. https://doi.org/10.1016/j.amjmed.2010.04.033CrossRefPubMed

21.

Patel S, Choyee S, Uyanne J, Nguyen AL, Lee P, Sedghizadeh PP, Kumar SKS, Lytle J, Shi S, Le AD (2012) Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines. Oral Dis 18:625–632. https://doi.org/10.1111/j.1601-0825.2012.01911.xCrossRefPubMed

22.

Schiodt M, Reibel J, Oturai P, Kofod T (2014) Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system. Oral Surg Oral Med Oral Pathol Oral Radiol 117:204–213. https://doi.org/10.1016/j.oooo.2013.10.010CrossRefPubMed

23.

Bedogni A, Fedele S, Bedogni G, Scoletta M, Favia G et al (2014) Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease. Br J Oral Maxillofac Surg 52:603–608. https://doi.org/10.1016/j.bjoms.2014.04.009CrossRefPubMed

24.

Topaloglu G, Koseoglu OT, Karaca C, Kosemehmetoglu K (2017) The effect of chronic dental inflammation on development of Stage 0 medication-related osteonecrosis of the jaw. J Craniomaxillofac Surg 45:1158–1164. https://doi.org/10.1016/j.jcms.2017.05.003CrossRefPubMed

25.

Rosenberg AE, Khurana JS (2016) Osteomyelitis and osteonecrosis. Diagn Histopathol 22:355–368. https://doi.org/10.1016/j.mpdhp.2016.09.005CrossRef

26.

Yamazaki T, Yamori M, Yamamoto K, Saito K, Asai K, Sumi E, Goto K, Takahashi K, Nakayama T, Bessho K (2012) Risk of osteomyelitis of the jaw induced by oral bisphosphonates in patients taking medications for osteoporosis: a hospital-based cohort study in Japan. Bone 51:882–887. https://doi.org/10.1016/j.bone.2012.08.115CrossRefPubMed

27.

Yoshida T, Watanabe T, Akizuki S, Okishio Y, Fujikawa N, Mori A, Fukuhara S, Asai K, Bessho K (2021) Adverse events caused by the discontinuation of anti-resorptive agents during treatment for anti-resorptive agent-related osteonecrosis of the jaw: a single-center cohort study. J Oral Maxillofac Surg Med Pathol 33:115–119. https://doi.org/10.1016/j.ajoms.2020.09.002CrossRef

28.

Watanabe T, Asai K, Fukuhara S, Uozumi R, Bessho K (2021) Effectiveness of surgery and hyperbaric oxygen for antiresorptive agent-related osteonecrosis of the jaw: a subgroup analysis by disease stage. PLoS One 16:e0244859. https://doi.org/10.1371/journal.pone.0244859CrossRefPubMedPubMedCentral

29.

Yoshikawa BA, Cunha BA (2002) Osteomyelitis in elderly patients. Clin Infect Dis 35:287–293. https://doi.org/10.1086/341417CrossRef

30.

Shin JW, Kim JE, Huh KH, Yi WJ, Heo MS, Lee SS, Choi SC (2019) Clinical and panoramic radiographic features of osteomyelitis of the jaw: a comparison between antiresorptive medication-related and medication-unrelated conditions. Imaging Sci Dent 49:287–294. https://doi.org/10.5624/isd.2019.49.4.287CrossRefPubMedPubMedCentral

31.

Aghaloo TL, Dry SM, Mallya S, Tetradis S (2014) Stage 0 osteonecrosis of the jaw in a patient on denosumab. J Oral Maxillofac Surg 72:702–716. https://doi.org/10.1016/j.joms.2013.09.008CrossRefPubMedPubMedCentral

32.

Mawardi H, Treister N, Richardson P, Anderson K, Munshi N, Faiella RA, Woo SB (2009) Sinus tracts-an early sign of bisphosphonate-associated osteonecrosis of the jaws? J Oral Maxillofac Surg 67:593–601. https://doi.org/10.1016/j.joms.2008.09.031CrossRefPubMed

33.

Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiakovou E, Christoulas D, Terpos E, Bamias A (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117–120. https://doi.org/10.1093/annonc/mdn554CrossRefPubMed

34.

Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137–145. https://doi.org/10.1093/annonc/mdn526CrossRefPubMed

35.

Aguirre JI, Akhter MP, Kimmel DB, Pingel JE, Williams A, Jorgensen M, Kesavalu L, Wronski TJ (2012) Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis. J Bone Miner Res 27:2130–2143. https://doi.org/10.1002/jbmr.1669CrossRefPubMed

36.

Otto S, Tröltzsch M, Jambrovic V, Panya S, Probst F, Ristow O, Ehrenfeld M, Pautke C (2015) Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development? J Craniomaxillofac Surg 43:847–854. https://doi.org/10.1016/j.jcms.2015.03.039CrossRefPubMed

Title: Nonexposed antiresorptive agent-related osteomyelitis of the jaw: a single-center cohort study
Authors: Takuma Watanabe
Takeshi Yoshida
Sachi Akizuki
Shigeki Yamanaka
Kazumasa Nakao
Shizuko Fukuhara
Keita Asai
Ryuji Uozumi
Kazuhisa Bessho
Publication date: 09-05-2022
Publisher: Springer Nature Singapore
Keywords: Wound Debridement
Osteonecrosis
Osteomyelitis
Published in: Journal of Bone and Mineral Metabolism / Issue 4/2022
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-022-01329-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2022

Association between non-alcoholic fatty liver disease and bone turnover markers in southwest China

Sarcopenia: an unsolved problem after hip fracture

Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease

Fracture risk and impact of osteoporosis in patients with Parkinson’s disease: a nationwide database study

Hypocalcemia in hospitalized patients with COVID-19: roles of hypovitaminosis D and functional hypoparathyroidism

Correlation between vitamin D metabolites and rheumatoid arthritis with osteoporosis by ultra-high-performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials